Synthesis and Evaluation of New Sartan Derivatives

Bertsetseg Dalaijargal

Donghua University

Le Mi

Donghua University

Zhuo Wu

Donghua University

Yao Yin

Donghua University

Hongyu Liang

Donghua University

Yan Qiu

Pudong New Area People's Hospital

Yi-Jia Yan

Donghua University

Hui Jin

Pudong New Area People's Hospital

Zhi-Long Chen (✉ zlchen1967@qq.com)

Donghua University

Research Article

Keywords: Hypertension, anti-hypertension, Prodrug, AT1 receptor blockers

Posted Date: January 20th, 2022

DOI: <https://doi.org/10.21203/rs.3.rs-1262787/v1>

License: This work is licensed under a Creative Commons Attribution 4.0 International License.

[Read Full License](#)

Abstract

As prodrugs series of new sartan-derived molecules were designed, synthesized, and evaluated. Most of the synthesized compounds could decrease blood pressure efficiently in spontaneously hypertensive rats. It could be ratiocinated that the original drugs could be released from the prodrugs exactly at the connecting position catalyzed by the hydrolyzation enzymes. The maximal response of mean blood pressure (MBP) lowered 70.2 ± 5.0 mmHg (compound **1**) and 61.2 ± 1.0 mmHg (compound **4**) at 10 mg/kg after oral administration, and the antihypertensive effect lasted beyond 24 h, which performed better than Losartan and were similar with Telmisartan. Pharmacokinetics test results of **1** were consistent with its anti-hypertension effects *in vivo*. The safety of new compounds was confirmed by the influence on the rats' heart rates and other symptoms which couldn't been observed during whole process. Thence, compounds **1** and **4** may be considered as potential antihypertension drug candidates.

1. Introduction

Hypertension is the main risk factor in cerebrovascular disease, coronary heart disease, and renal vascular disease^[1, 2]. The renin-angiotensin system (RAS) plays a vital role in the regulation of blood pressure and fluid balance^[3]. AT₁ receptor blockers (ARBs or sartans) act as antihypertensive drugs by blocking Angiotensin II to stimulate AT₁ receptors. Several ARBs have been developed, such as losartan, candesartan, and telmisartan which is one of the most widely used ARBs in clinics with the characteristics of high potency, long-lasting, and low toxicity^[4 - 6]. However, long-term use of sartans could cause symptoms such as nausea and headache, so it is still necessary to develop effective, bioavailable, and safe antihypertension drugs^[7 - 9].

Hypertension is mostly caused by a combination of heterogeneous factors such as genetic background and renal or endocrine disorders, and clusters often with other chronic kidney disease or cardiovascular disease, such as heart failure, thrombosis, myocardial infarction, ischemic stroke, etc.^[10]. Thus one-drug therapy is usually insufficient for most patients. The use of two-drug combination therapy was recommended in the 2018 ESC/ESH guideline; namely, an angiotensin receptor blocker (ARB) is usually matched with a calcium channel blocker (CCB) or diuretic as the initial treatment to control blood pressure (BP)^[11] because of the existence of complementary effects between different antihypertension drugs^[12]. In addition, hypertension patients with atherogenic dyslipidemia are recommended to administrate antihypertension drugs together with Aspirin or Statins to reduce the incidence of cardiovascular events. However, for the patients receiving two or more pills, their adherence to treatment in practice is about 25–65%, complying with the prescribed treatment regimen^[13].

Single-pill combination (SPC) therapy with two or more drugs in a single tablet has been used to simplify the treatment by reducing the number of pills to be taken. It has shown better BP control than those given two or more drugs separately and can maintain all or most of the expected effects of the different agents contained^[14]. For example, as an SPC of sacubitril and valsartan, Entresto has a good blood pressure

reduction effect and can significantly reduce hospitalization or mortality in patients with heart failure^[15]. Conjugation of two drug molecules with suitable linkers into one new molecule is another strategy for the treatment of patients with one or several cardiovascular related diseases^[16]. As a prodrug, this new molecule usually has dual activities with a higher bioavailability and lower toxicity than the simple combination of two drugs^[17]. Here series of new sartan-derived molecules conjugated with cardiovascular drugs, namely, Telmisartan and Candesartan with antithrombotic agent Aspirin and calcium channel blocker Nifedipine, Telmisartan with Candesartan, and Telmisartan with itself, were synthesized, and their antihypertension activities were evaluated as prodrugs.

2. Results And Discussion

2.1 Chemistry

The preparation of compounds (**1-6**) is depicted in Schemes 1. The hydrogen of -COOH of telmisartan was replaced by chloride methyl group to obtain compound **2a**, while by hydroxyethyl group to give compound **2b**. Compound **2a** was reacted with carboxylic acid compounds (**1a**, **1b**, **1e**) to give compounds **1-3**. Compound **4** was generated after the reaction of **2b** with compound **1a** under the existence of DCC and DMAP.

The preparation of compounds (**5-6**) is described in Schemes 2. The commercially available compound **1f** was reacted with chloromethyl sulfurochloridate under $\text{Bu}_4\text{N}^+\cdot\text{HSO}_4$ as catalyst and NaHCO_3 as a base to obtain compound **2c**. Compound **2c** was reacted with K_2CO_3 and NaI followed with carboxylic acid (**1a**, **1b**) in DMF to generate compounds **5** and **6**.

2.2. Biological evaluation

2.2.1. *In vivo* anti-hypertension effects

The anti-hypertensive efficiency of compounds **1-6** (5 and 10 mg/kg) was investigated in SHR (spontaneously hypertensive rats) after oral administration with Losartan and Telmisartan (10 mg/kg) as positive control drugs (Figure 2). All compounds could decrease blood pressure significantly at 5 and 10 mg/kg dosages. Among them, MBP of compound **4** was 61.2 ± 0.1 mmHg, and **1** was 70.2 ± 5.0 mmHg, which was higher than Losartan and almost equal to Telmisartan (72.2 ± 2.3) at 10mg/kg. The antihypertensive effects of **1** and **4** were sustained for at least 24 h. It could be ratiocinated that the original drugs could be released from the prodrugs exactly at the connecting position through hydrolyzation by the mammalian metabolism enzymes to take their anti-hypertension effects. The safety was confirmed by the influence on the rats' heart rates and other symptoms which couldn't been observed during the whole process.

2.2.3. Pharmacokinetics test

LC-MS (Liquid chromatography-mass spectrometry) method was used to monitor the concentration of compound **1** in plasma which showed the highest antihypertensive activity after an oral administration (10 mg/kg). There was no difference in the bioavailability between Telmisartan (positive control) and compound **1**. The mean plasma concentration-time curves ($n = 6$) of **1** are shown in (Figure 3). The bioavailability of compound **1** after oral administration was 48.01% ($F = AUC_{0-t}(\text{test})/AUC_{0-t}(\text{reference}) \times 100\%$), which was almost the same with Telmisartan (48.8%), and the AUC_{0-78} of compound **1** ($688.50 \pm 20.88 \cdot h$) was also similar with Telmisartan ($649.00 \pm 8.07 \cdot h$, $p < 0.05$). These results were consistent with its anti-hypertension effects *in vivo*.

3. Conclusions

As pro-drugs series of novel sartan derivatives were prepared. Most of them could decrease blood pressure efficiently in SHR. It could be ratiocinated that the original drugs could be released from the prodrugs exactly at the connecting position catalyzed by the hydrolyzation enzymes. The safety was confirmed by the influence on the rats' heart rates and other symptoms which couldn't been observed during whole process. Pharmacokinetics test results of compound **1** were consistent with its anti-hypertension effects *in vivo*. Among them, compounds **1** and **4** could reduce the blood pressure more effectively than Losartan, so **1** and **4** could be considered as potential anti-hypertension drug candidates and deserve further investigation. Other effects, such as the antithrombotic effects of aspirin and the synergistic effects of two drugs released from their prodrugs, will be further studied.

4. Experimental Section

4.1 Chemistry

Most of the reagents were bought from commercial suppliers and used without purification. The progress of reactions was monitored through TLC (thin layer chromatography). 300 - 400 meshes silica gel was selected for the purification in column chromatography. An electro thermal melting point apparatus was applied to measure melting points (m. p.). ^{13}C NMR (100 MHz) and ^1H NMR (400 MHz) spectra were recorded on a spectrometer with CDCl_3 or $\text{DMSO}-d_6$ as solvent and Me_4Si as internal standard. ESI-MS spectra were tested on a Micro-mass-triple-quadrupole-mass spectrometer.

4.2.1 General procedure for the synthesis of chloromethyl 4'-((1,7'-dimethyl-2'-propyl-1H,3'H-[2,5'-bibenzo[d]imidazol]-3'-yl) methyl)-[1,1'-biphenyl]-2-carboxylate (**2a**):

4'-((1,7'-dimethyl-2'-propyl-1H,3'H-[2,5'-bibenzo[d]imidazol]-3'-yl)methyl)-[1,1'-biphenyl]-2-carboxylic acid (2 g, 3.89 mmol) was reacted with chloromethyl sulfurochloridate (0.03 mL, 4 mmol) under the existence of $\text{Bu}_4\text{N}^+ \cdot \text{HSO}_4$ (6.6 g, 19.45 mmol) and NaHCO_3 (1.6 g, 19.45 mmol) in the mixed solution of DCM (50 mL)

and H₂O (50 mL) at rt. After stirred for 1h, the reaction was quenched with water (100 mL) and extracted with EtOAc (100 mL × 3). The mixed organic layer was dried over MgSO₄ and concentrated in vacuo to obtain an off-white solid, purified by column chromatography [eluent: petroleum ether/ethyl acetate (4:1, v/v)] to give the pure product **2a** as white solid in 72% yield. ¹H NMR (400 MHz, DMSO-*d*₆) δ: 7.87 (ddd, *J* = 17.9, 7.4, 2.6 Hz, 2H, PhH), 7.65 - 7.51 (m, 2H, PhH), 7.48 - 7.37 (m, 3H, PhH), 7.37 - 7.30 (m, 3H, PhH), 7.26 - 7.21 (m, 2H, PhH), 7.12 (d, *J* = 8.1 Hz, 2H, PhH), 6.34 (s, 2H, -O-CH₂-Cl), 5.49 (s, 2H, -CH₂-Ph), 3.85 (s, 3H, -NCH₃), 3.01 - 2.92 (m, 2H, -CH₂CH₂CH₃), 2.78 (s, 3H, -CH₃), 1.90 (h, *J* = 7.4 Hz, 2H, -CH₂CH₂CH₃), 1.07 (t, *J* = 7.3 Hz, 3H, -CH₂CH₂CH₃). MS (ESI) *m/z*: 563.2 [M+ H]⁺.

4.2.2 2-Hydroxyethyl 4'-((1,7'-dimethyl-2'-propyl-1H,3'H-[2,5'-bibenzo[d]imidazole]-3'-yl)methyl)-[1,1'-biphenyl]-2-carboxylate (**2b**):

The mixture of 4'-((1,7'-dimethyl-2'-propyl-1H,3'H-[2,5'-bibenzo[d]imidazol]-3'-yl) methyl)-[1,1'-biphenyl]-2-carboxylic acid (500 mg, 0.97 mmol), HOCH₂CH₂OH (30 mg, 0.48 mmol), DCC (400 mg, 1.94 mmol), DMAP (12.5 mg, 0.1 mmol) and dimethylformamide (50 mL) was stirred for 2.5 h, then extracted with EtOAc (50 mL × 3). The organic phase was dried over MgSO₄, and concentrated under a reduced pressure. The obtained residue was purified by column chromatography [eluent: petroleum ether/EtOAc (2:1, v/v)] to provide the pure **2b** as white solid. Yield: 81%; m.p.: 213-216 °C. ¹H NMR (400 MHz, DMSO-*d*₆) δ: 7.86 (d, *J* = 1.5 Hz, 1H, PhH), 7.82 - 7.74 (m, 1H, PhH), 7.72 - 7.57 (m, 3H, PhH), 7.53 (dp, *J* = 7.3, 2.3 Hz, 4H, PhH), 7.43 (d, *J* = 1.5 Hz, 1H, PhH), 7.35 - 7.17 (m, 4H, PhH), 5.34 (d, *J* = 1.2 Hz, 2H, -CH₂-Ph), 4.40 (t, *J* = 3.0 Hz, 2H, -CH₂CH₂-OH), 3.86 (s, 3H, -NCH₃), 3.80 (s, 3H, -CH₃), 2.60 (t, *J* = 7.9 Hz, 2H, -CH₂CH₂-OH), 2.49 (h, *J* = 9.5 Hz, 2H, -CH₂CH₂CH₃), 1.58 (h, *J* = 7.9 Hz, 2H, -CH₂CH₂CH₃), 0.88 (t, *J* = 8.0 Hz, 3H, -CH₂CH₂CH₃). MS (ESI) *m/z*: 559.2 [M+H]⁺.

4.2.3 Chloromethyl 2-ethoxy-1-((2'-(1-trityl-1H-tetrazol-5-yl)-[1,1'-biphenyl]-4-yl) methyl) -1H-benzo[d]imidazole-4-carboxylate (**2c**):

2-Ethoxy-1-((2'-(1-trityl-1H-tetrazol-5-yl)-[1,1'-biphenyl]-4-yl)methyl)-1H-benzo[d]imidazole-7-carboxylic acid (2 g, 2.93 mmol) was reacted with chloromethyl sulfurochloridate (0.03 mL, 4 mmol) under the existence of Bu₄N⁺·HSO₄ (6.6 g, 19.45 mmol) and NaHCO₃ (1.6 g, 19.45 mmol) in the mixed solution of DCM (50 mL) and H₂O (50 mL) at rt. After stirred for 1h, the reaction was quenched with water (100 mL) and extracted with EtOAc (100 mL × 3). The combined organic layer was dried over MgSO₄ and concentrated in vacuo to obtain an off-white solid which was purified by column chromatography [eluent: petroleum ether/ethyl acetate (4:1, v/v)] to give the pure product **2c**. Yield: 72.1%. ¹H NMR (400 MHz, DMSO-*d*₆) δ: 7.81 (dd, *J* = 7.4, 1.6 Hz, 1H, PhH), 7.73 (dd, *J* = 7.5, 1.7 Hz, 1H, PhH), 7.52 (m, *J* = 7.2, 4.7, 2.2 Hz, 4H, PhH), 7.49 (dd, *J* = 7.5, 2.0 Hz, 1H, PhH), 7.42 - 7.28 (m, 15H, PhH), 7.18 (m, *J* = 11.2, 7.4, 2.0 Hz, 2H, PhH),

7.08 - 6.96 (m, 2H, PhH), 5.34 (d, J = 1.5 Hz, 2H, -CH₂-Ph), 4.67 (s, 2H, -O-CH₂-Cl), 4.38 (q, J = 8.0 Hz, 2H, -OCH₂CH₃), 2.39 (t, 3H, -OCH₂CH₃). MS (ESI) m/z : 731.3 [M+H]⁺.

4.3. General procedure for the synthesis of 1 - 3:

A mixture of K₂CO₃ (270 mg, 1.95 mmol), NaI (292.3 mg, 1.95 mmol), compound **2a** (220 mg, 0.39 mmol) and DMF (50 mL) was stirred for 0.5 h at rt, then **1e** (129.6 mg, 0.39 mmol), or **1a** (200 mg, 0.39 mmol) or **1b** (70 mg, 0.39 mmol) was added slowly to the reaction mixture. After stirring for another 1.5 h at rt, 100 mL water was added to the mixture and extracted with EtOAc (100 mL × 2). The organic phase was dried with MgSO₄ and concentrated in vacuo to obtain an off-white solid, purified by column chromatography [eluent: petroleum ether/EtOAc (4:1, v/v)] to provide a pure white solid product (**1 - 3**).

4.3.1 Methylene-bis(4'-((1,7'-dimethyl-2'-propyl-1H,3'H-[2,5'-bibenzo[d]imidazol]-3'-yl) methyl)-[1,1'-biphenyl]-2-carboxylate) (1):

Compound **1** was prepared following the above general procedure. Yield: 77.3%. ¹H NMR (400 MHz, CDCl₃) δ : 7.87 (m, J = 17.9, 7.4, 2.6 Hz, 4H, PhH), 7.64 - 7.50 (m, 4H, PhH), 7.48 - 7.38 (m, 6H, PhH), 7.36 - 7.30 (m, 6H, PhH), 7.26 - 7.22 (m, 4H, PhH), 7.12 (d, J = 8.1 Hz, 4H, PhH), 5.71 (s, 2H, -O-CH₂-O-), 5.51 (s, 4H, -CH₂-Ph), 3.85 (s, 6H, -NCH₃), 3.03 - 2.91 (m, 4H, -CH₂CH₂CH₃), 2.78 (s, 6H, -CH₃), 1.90 (h, J = 7.4 Hz, 4H, -CH₂CH₂CH₃), 1.07 (t, J = 7.3 Hz, 6H, -CH₂CH₂CH₃). ¹³C NMR (101 MHz, DMSO-*d*₆) δ : 165.72, 156.07, 153.97, 142.62, 142.44, 141.51, 139.28, 136.60, 136.12, 134.70, 132.21, 130.86, 129.68, 128.86, 128.65, 128.22, 127.49, 126.30, 123.28, 121.98, 121.73, 118.63, 110.28, 109.10, 79.98, 45.97, 39.96, 39.76, 31.50, 28.68, 20.59, 16.41, 13.74. MS (ESI) m/z calcd for: C₆₇H₆₁N₈O₄ [M+H]⁺: 1041.5; found: 1041.4.

4.3.2 ((2-Acetoxybenzoyl)oxy)methyl 4'-((1,7'-dimethyl-2'-propyl-1H,3'H-[2,5'-bibenzo [d] imidazol]-3'-yl)methyl)-[1,1'-biphenyl]-2-carboxylate (2):

Compound **2** was prepared with the above general procedure. Yield: 71.9%. ¹H NMR (400 MHz, DMSO-*d*₆) δ : 7.90 (dd, J = 7.9, 1.7 Hz, 1H, PhH), 7.80 (dd, J = 7.8, 1.3 Hz, 1H, PhH), 7.71 (ddd, J = 15.6, 7.5, 1.6 Hz, 2H, PhH), 7.64 (tdd, J = 7.6, 5.1, 1.5 Hz, 2H, PhH), 7.59 - 7.54 (m, 1H, PhH), 7.54 - 7.45 (m, 2H, PhH), 7.38 (ddd, J = 8.8, 7.7, 1.3 Hz, 2H, PhH), 7.31 - 7.17 (m, 5H, PhH), 7.10 (d, J = 8.1 Hz, 2H, PhH), 5.93 (d, J = 17.2 Hz, 2H, -O-CH₂-O-), 5.51 (d, J = 16.6 Hz, 2H, -CH₂-Ph), 3.82 (s, 3H, -NCH₃), 2.88 (dd, J = 9.0, 6.2 Hz, 2H, -CH₂CH₂CH₃), 2.65 (s, 3H, -COOCH₃), 2.18 (s, 3H, -CH₃), 1.79 (p, J = 7.4 Hz, 2H, -CH₂CH₂CH₃), 0.99 (t, J = 7.3 Hz, 3H, -CH₂CH₂CH₃). ¹³C NMR (101 MHz, DMSO-*d*₆) δ : 169.09, 167.68, 167.25, 159.08, 152.90, 152.43, 150.94, 141.86, 141.47, 137.42, 136.46, 135.57, 134.63, 134.34, 133.90, 132.79, 131.83, 130.58, 130.51, 129.38, 128.69, 128.06, 127.22, 126.98, 126.87, 126.78, 124.22, 122.70, 122.64, 122.30, 119.60,

111.15, 109.52, 82.70, 46.76, 31.40, 29.01, 20.92, 20.15, 18.56, 13.53. MS (ESI) m/z calcd for:

$C_{43}H_{39}N_4O_6$ $[M+H]^+$: 707.3; found: 707.4.

4.3.3 3-(((4'-((2'-Ethyl-1,7'-dimethyl-1H, 3'H-[2,5'-bibenzo[d]imidazol]-3'-yl) methyl)-[1,1'-biphenyl]-2-carbonyl)oxy)methyl) 5-methyl 2,6-dimethyl-4- (3-nitrophenyl) -1,4- dihydropyridine -3,5-dicarboxylate (3):

Compound **3** was prepared with the above general procedure. Yield: 77.3%. 1H NMR (400 MHz, DMSO- d_6) δ : 9.26 (s, 1H, PhH), 7.90 (dp, J = 4.4, 2.3 Hz, 2H, PhH), 7.75 (d, J = 1.5 Hz, 1H, PhH), 7.65 - 7.62 (m, 1H, PhH), 7.61 - 7.53 (m, 3H, PhH), 7.52 - 7.47 (m, 2H, PhH), 7.44 - 7.38 (m, 2H, PhH), 7.35 (d, J = 7.7 Hz, 1H, PhH), 7.28 - 7.17 (m, 4H, PhH), 7.12 (d, J = 8.1 Hz, 2H, PhH), 5.75 - 5.63 (m, 2H, -O-CH₂-O-), 5.61 (d, J = 5.4 Hz, 2H, -CH₂-Ph), 3.82 (s, 3H, -NCH₃), 3.52 (s, 3H, -COOCH₃), 2.91 (t, J = 7.6 Hz, 2H, -CH₂CH₂CH₃), 2.64 (s, 3H, Ph-CH₃), 2.28 (d, J = 8.8 Hz, 6H, Ph-CH₃), 1.81 (q, J = 7.5 Hz, 2H, -CH₂CH₂CH₃), 0.99 (t, J = 7.4 Hz, 3H, -CH₂CH₂CH₃). ^{13}C NMR (101 MHz, DMSO- d_6) δ : 166.84, 165.89, 164.82, 156.15, 153.96, 149.52, 148.93, 147.57, 146.06, 141.47, 139.38, 136.56, 136.08, 134.71, 133.90, 129.52, 128.97, 128.62, 128.24, 127.43, 126.28, 123.22, 122.02, 121.77, 121.50, 121.15, 118.55, 110.32, 109.17, 101.65, 99.33, 78.99, 50.85, 46.03, 31.68, 28.72, 20.66, 18.48, 18.15, 16.42, 13.78. MS (ESI) m/z calcd for: $C_{50}H_{47}N_6O_8$ $[M+H]^+$: 859.2; found: 859.3.

4.4 General procedure for the synthesis of 4:

A mixture of compounds **2b** (877.0 mg, 1.57 mmol) and **1a** (808 mg, 1.57 mmol), DCC (323.9 mg, 1.57 mmol), DMAP (191.8 mg, 1.57 mmol), and dimethylformamide (50 mL) was stirred for 2.5 h. The mixture was extracted with EtOAc (50 mL $\times$ 2), and the organic phase was collected and drained with MgSO₄. After filtration, the solvent was removed under reduced pressure, and the residue was purified by column chromatography [eluent: petroleum ether/EtOAc (2:1, v/v)] to provide the pure **4** as white solid.

4.4.1 Ethane-1,2-diylbis (4'-((1,7'-dimethyl-2'-propyl-1H, 3'H-[2,5'-bibenzo [d] imidazol]-3'-yl) methyl)-[1,1'-biphenyl]-2-carboxylate) (4):

Compound **4** was prepared as the above general procedure. Yield: 89.1%. 1H NMR (400 MHz, DMSO- d_6) δ : 7.70 (s, 2H, PhH), 7.66 - 7.56 (m, 4H, PhH), 7.52 (ddd, J = 7.5, 5.9, 1.6 Hz, 4H, PhH), 7.47 (s, 2H, PhH), 7.37 (t, J = 7.6 Hz, 2H, PhH), 7.31 (d, J = 7.7 Hz, 2H, PhH), 7.27 - 7.13 (m, 8H, PhH), 7.03 (d, J = 7.9 Hz, 4H, -O-CH₂-CH₂-O-), 5.52 (s, 4H, -CH₂-Ph), 3.97 (s, 4H, -CH₂CH₂CH₃), 3.79 (s, 6H, -NCH₃), 2.84 (t, 4H), 2.62 (s, 6H, Ph-CH₃), 1.77 (h, J = 7.4 Hz, 4H, -CH₂CH₂CH₃), 0.94 (t, J = 7.3 Hz, 6H, -CH₂CH₂CH₃). ^{13}C NMR (101 MHz, DMSO- d_6) δ : 167.16, 156.07, 153.99, 142.65, 142.49, 141.00, 139.67, 136.61, 135.98, 134.71, 131.58, 130.54, 130.14, 129.30, 128.53, 128.21, 127.39, 126.16, 123.33, 121.96, 118.64, 110.27, 109.09, 62.13,

45.94, 31.64, 28.68, 20.60, 16.41, 13.74. MS (ESI) m/z calcd for: $C_{68}H_{63}N_8O_4$ $[M+H]^+$: 1054.5; found: 1055.4.

4.5 General procedure for the synthesis of compounds 5 and 6:

A mixture of compound **2c** (285.1 mg, 0.39 mmol), DMF (50 mL), K_2CO_3 (270 mg, 1.95 mmol), and NaI (292.3 mg, 1.95 mmol) was stirred for 0.5 h at rt, then **1a** (200 mg, 0.39 mmol) or **1b** (70 mg, 0.39 mmol) was added. The mixture was stirred for another 1.5 h at rt followed by the addition of 100 mL water and extracted with EtOAc (100 mL $\times$ 2). The combined organic layer was dried over $MgSO_4$ and concentrated. The solid residue was purified by column chromatography [eluent: petroleum ether/EtOAc (4:1, v/v)] to give a white solid. Then solid was dissolved in 50 mL MeOH with a 3 M hydrochloric acid solution (3 mL). The mixture was stirred for 1 h. The solvent was removed, and the residue was purified by column chromatography [elution: petroleum ether/EtOAc (1:1, v/v)] to provide the pure product **5** or **6** as white solid.

4.5.1 ((4'-((1,7'-Dimethyl-2'-propyl-1H,3'H-[2,5'-bibenzo[d]imidazol]-3'-yl)methyl)-[1, 1'-biphenyl]-2-carbonyl)oxy)methyl-1-((2'-(1H-tetrazol-5-yl)-[1,1'-biphenyl]-4-yl)methyl)-2-ethoxy-1H-benzo [d] imidazole-7-carboxylate (**5**):

Compound **6** was prepared as the above procedure. Yield: 81.9%. 1H NMR (400 MHz, $DMSO-d_6$) δ : 7.90 (dd, J = 7.5, 1.7 Hz, 1H, PhH), 7.86 (dd, J = 7.5, 1.7 Hz, 1H, (2H) PhH), 7.81 - 7.75 (m, 1H (3H), PhH), 7.67 (dt, J = 7.5, 1.7 Hz, 1H, PhH), 7.66 - 7.59 (m, 4H), 7.59 - 7.55 (m, 3H, PhH), 7.55 - 7.51 (m, 2H, PhH), 7.51 - 7.47 (m, 2H, PhH), 7.44 (t, J = 7.5 Hz, 1H, PhH), 7.35 - 7.27 (m, 2H, PhH), 7.21 (s, 2H, PhH), 7.12 - 7.06 (m, 2H, PhH), 7.05 - 6.99 (m, 2H, -O-CH₂-O-), 5.34 (d, J = 1.2 Hz, 4H, -CH₂-Ph), 4.38 (q, J = 8.0 Hz, 2H, -CH₂CH₃), 3.69 (s, 3H, -NCH₃), 2.60 (t, J = 7.9 Hz, 2H, -CH₂CH₂CH₃), 2.49 (s, 3H, Ph-CH₃), 1.59 (p, J = 7.9 Hz, 2H, -CH₂CH₂CH₃), 1.51 (t, J = 8.0 Hz, 3H, -CH₂CH₃), 0.88 (t, J = 8.0 Hz, 3H, -CH₂CH₂CH₃). ^{13}C NMR (101 MHz, $DMSO-d_6$) δ : 167.68, 167.34, 159.08, 158.36, 154.61, 152.90, 152.43, 141.86, 141.47, 140.38, 138.26, 137.42, 136.46, 136.06, 135.79, 135.57, 134.63, 134.18, 133.90, 132.79, 130.58, 130.55, 130.50, 129.38, 129.33, 129.21, 128.69, 128.06, 127.71, 127.50, 127.22, 126.87, 126.78, 126.42, 123.33, 122.70, 122.43, 122.30, 121.39, 119.60, 116.00, 111.15, 109.52, 82.70, 66.69, 46.76, 46.24, 31.40, 29.01, 20.15, 18.56, 14.30, 13.53. MS (ESI) m/z calcd for: $C_{58}H_{51}N_{10}O_5$ $[M+H]^+$: 967.4; found: 967.3.

4.5.2 ((2-Acetoxybenzoyl) oxy) methyl 1-((2'-(1H-tetrazol-5-yl) -[1,1'-biphenyl] -4-yl) methyl)-2-ethoxy-1H-benzo[d]imidazole-7-carboxylate (**6**):

Compound **6** was prepared as the mentioned general procedure above. Yield: 86.4%. ^1H NMR (400 MHz, DMSO- d_6) δ : 7.97 (dd, J = 7.5, 2.0 Hz, 1H, PhH), 7.72 (m, J = 7.5, 1.5 Hz, 2H, PhH), 7.61 (m, 2H, PhH), 7.52 (td, J = 7.6, 2.0 Hz, 2H, PhH), 7.38 (t, J = 7.5 Hz, 2H, PhH), 7.24 (m, 2H, PhH), 6.86 (d, 4H, PhH), 6.15 (s, 2H, -CH₂-Ph), 5.52 (s, 2H, -O-CH₂-O), 4.6 (q, J = 8.0 Hz, 2H, -CH₂CH₃), 2.24 (s, 3H, -COOCH₃), 1.39 (t, J = 8.0 Hz, 3H, -CH₂CH₃). ^{13}C NMR (101 MHz, DMSO- d_6) δ : 169.09, 167.34, 167.25, 158.36, 154.61, 150.94, 140.38, 138.26, 136.06, 135.79, 134.34, 134.18, 131.83, 130.55, 130.50, 129.33, 129.21, 127.71, 127.50, 126.98, 126.42, 124.22, 122.64, 122.43, 121.39, 116.00, 82.70, 66.69, 46.24, 20.92, 14.30. MS (ESI) m/z calcd for: C₃₄H₂₉N₆O₇ [M+H]⁺: 633.2; found: 633.1.

5 Biological Activity Detection

5.1 The *in vivo* anti-hypertension assays

The antihypertension activities of new compounds were tested on SBP and DBP of SHR (250 ± 20 g, Beijing Vital River Lab Animal Co., Ltd., China). 15 Male SHRs were divided randomly into different groups: test compound groups, positive control group, negative control group. Every compound was suspended in 0.5% sodium carboxymethylcellulose solution and orally administered (5 and 10 mg/kg, respectively). Losartan and telmisartan (10 mg/kg) were fed as positive groups. The negative control groups were supplied with the same volume of sodium carboxymethylcellulose solution. Blood pressure and heart rates were detected 24 h by MPA - 2000 biological signal analysis system (Alcott Biotech, China). Six detections were operated in each part of blood pressure measurement. The means of the six values were taken as the SBP level and DBP level separately. The MBP (mean arterial pressure) was calculated with the formula: MBP = (SBP - DBP) / 3 + DBP. All compounds' data were presented as mean ± SD [18].

5.2 Pharmacokinetics Detection

LC-MS (Liquid chromatography-mass spectrometry) method was used to monitor the concentration of compound **1** in plasma. LC-MS-ESI mass spectrometer (Agilent) was used with a C18 column (2.1 mm x 150 mm, 3 mm) with mobile phases: (A) Sodium dihydrogen phosphate and (B) acetonitrile. The flow rate was 1 mL × min⁻¹, and the injection volume was 20 μL. The gradient elution program of mobile phase A: B (v/v) were 25:75, 30:70, 50:50. LC-MS spectral data of every sample were collected. The pharmacokinetic parameters were calculated with the Microsoft-excel program (DAS 2.0). 6 Male Wistar rats (200-250g, Shanghai Slac Lab Animal Company) were administrated with **1** (10 mg/kg).

Blood samples were collected from each rat with a retro-orbital puncture at pre-setting time intervals [0.5, 1, 2, 4, 6, 8, 12, 24, 48, 78h] into microfuge tubes containing heparin. The plasma samples were separated by centrifugation of the blood samples (4000 × g) at 4°C for 10 min. Plasma samples (200 μL) were collected, internal standard (100 μL) and acetonitrile (200 μL) were added. The mixture was vortexed for 1 min to remove proteins. The supernatant was filtered by filter (0.22 μm), and the obtained filtrate (20 μL) was tested in LC-MS. Linearity 3 was detected by extracting plasma standards at nominal concentrations

(2.0–5.0–10.0–50.0–100.0–500.0 ng/mL). The calibration line was generated by least-squares linear regression of PHR (the peak height ratio) of analyte/internal standard versus nominal concentration with weighted concentration^[19, 20].

5.3 Statistics

The data were analyzed with a one-way analysis of variance, and the results were expressed as means ± standard error. When all statistical significance was provided ($P < 0.05$), a nova one-way and t-test were used to compare with the control, and the probability value < 0.05 was considered to be significant. Pharmacokinetic parameters were acquired by software DAS.2.0. The animal research was accorded with the “Principles of Laboratory Animal Care” and permitted by IACUC.

Declarations

Acknowledgments

This work was funded by Shanghai Science & Technology Committee (No.19410711000; 20430730900; 20490740400 and 21430730100) and the Science & Technology Commission of Pudong-New-Area (No. PKJ-2019-Y31 and PKJ-2020-Y42).

Conflict of Interest

The authors declare no conflict of interest concerning this work.

References

1. Dorian N, Helena M, Anna S et al (2017) Lecithin derived from ω -3 PUFA fortified eggs decreases blood pressure in spontaneously hypertensive rats. *Sci. Rep-uk.*, 7, 1 - 11
2. Prashant N, Hardik G, Vijay P et al (2015) Management of hypertension-journey from single drug therapy to multitargeted ligand therapy: A clinical overview. *Fundam. Clin. Pharmacol.*, 10, 321 - 346
3. Peng YZ, Guang YY, Zhu ZW et al (2014) Antihypertensive effect of angiotensin-converting enzyme inhibitory peptide RVPSL on spontaneously hypertensive rats by regulating gene expression of the renin-angiotensin system. *J. Agr. Food Chem.*, 62, 912 - 917
4. Ntountaniotis D, Andreadelis L, Kellici T et al (2019) Host-guest interactions between candesartan and its prodrug candesartan cilexetil in complex with 2-Hydroxypropyl- β -cyclodextrin: On the biological potency for angiotensin II antagonism. *Mol Pharmaceut* 161:1255
5. Lauren BA, Jan AHD, Marko P et al (2019) Novel Therapeutic Approaches Targeting the Renin-Angiotensin System and Associated Peptides in Hypertension and Heart Failure. *Pharmacol Rev.*, 71(4): 539 - 570
6. Hazel MA, Michael C, William W, B. W.; et al (2015) The Comparative Efficacy and Safety of the Angiotensin Receptor Blockers in the Management of Hypertension and Other Cardiovascular Diseases. *Drug Saf.*, 38(1): 33 - 54

7. Vyas VK, Ghatge M (2010) Substituted benzimidazole derivatives as angiotensin II AT₁ receptor antagonists: A review, *Mini Rev. Med. Chem.*, 10, 1366 - 1384
8. Rossi S (ed) Australian Medicines Handbook 2006
9. Monge M 1, Lorthioir A, Bobrie G 1 et al (2013) New drug therapies interfering with the renin-angiotensin-aldosterone system for resistant hypertension. *J. Renin-Angio-Aldo S.*, 14, 285 - 289
10. Poulter NR, Prabhakaran D, Caulfield M, Hypertension et al (2015) *Lancet.*, 386 (9995): 801- 812
11. Williams B, Mancia G, Spiering W et al (2018) 2018 ESC/ESH Guidelines for the management of arterial hypertension. *Eur. Heart J.*, 39 (33): 3021- 3104
12. Paulis L, Steckelings UM, Unger T et al (2012) Key advances in antihypertensive treatment. *Nature Reviews Cardiology.*, 9 (5): 276 - 285
13. Gupta P, Patel P, Strauch B et al (2017) Biochemical Screening for Nonadherence Is Associated With Blood Pressure Reduction and Improvement in Adherence. *Hypertension*, 70 (5): 1042 - 1048
14. Ferdinando I, Karl W, Krzysztof N et al (2017) Practical Applications for Single Pill Combinations in the Cardiovascular Continuum. *Card. Fail. Rev.*, 3(1): 40 - 45
15. George GS, Amresh R (2020) ; Understanding the early mortality benefit observed in the PARADIGM-HF trial: considerations for the management of heart failure with sacubitril/valsartan. *Vasc Health Risk Manag.*, 16: 41 - 51
16. Ha D, Lee YJ, Chun Y et al (2019) Comparison of signal detection between statin and statin/ezetimibe fixed-dose combination using the Korea adverse events reporting system database., 2005 - 2016. *Int. J. Clin. Pharm-net.*, 57 (10): 489 - 499
17. Daniela HJ, Guilherme FSF, Diego EC et al (2016) The Prodrug Approach: A Successful Tool for Improving Drug Solubility. *Molecules.*, 21(1): 42
18. Zhu W, Bao X, Ren H et al (2016) *N*-Phenyl indole derivatives as AT₁ antagonists with anti-hypertension activities: Design, synthesis and biological evaluation. *Eur. J. Med. Chem.*, 115, 161 - 178
19. Sandall JM, Millership JS, Collier PS et al (2006) Development and validation of an HPLC method for the determination of spironolactone and its metabolites in paediatric plasma samples. *J Chromatogr B Analyt Technol Biomed Life Sci.* 24, 839(1-2): 36 - 44
20. Xiao-Lu B, Wei-Bo Z, Tian-Li S et al (2017) Design, synthesis and evaluation of novel angiotensin II receptor 1 antagonists with antihypertensive activities. *RSC Adv.*, 7, 26401–26410

Schemes

Schemes 1 and 2 are available in the Supplemental Files section

Figures

telmisartan
1a

aspirin
1b

nifedipine
1c

candesartan
1d

1e

1f

Figure 1

Structure of compounds **1a-f**.

Figure 2

Effects of compound 1-6 on MBP of SHR (n = 6, *P<0.05, **P<0.01 VS negative control; and compound 1 and 4 on MBP (*P<0.05, **P<0.01 VS Losartan).

Figure 3

Plasma concentrations of compound **1** in the rat after single oral administration at 10 mg/kg (n = 6, mean $\pm$ SD).

Supplementary Files

This is a list of supplementary files associated with this preprint. Click to download.

- [Scheme1.jpg](#)
- [Scheme2.jpg](#)
- [renamed40fc4.docx](#)